Edition:
United States

Minerva Neurosciences Inc (NERV.OQ)

NERV.OQ on NASDAQ Stock Exchange Global Market

5.95USD
15 Dec 2017
Change (% chg)

$0.20 (+3.48%)
Prev Close
$5.75
Open
$5.85
Day's High
$6.00
Day's Low
$5.65
Volume
368,224
Avg. Vol
50,143
52-wk High
$14.00
52-wk Low
$4.90

Latest Key Developments (Source: Significant Developments)

Minerva Neurosciences names Richard Russell president
Monday, 11 Dec 2017 04:41pm EST 

Dec 11 (Reuters) - Minerva Neurosciences Inc ::MINERVA NEUROSCIENCES NAMES RICHARD RUSSELL PRESIDENT.MINERVA NEUROSCIENCES INC - REMY LUTHRINGER WILL CONTINUE AS CHIEF EXECUTIVE OFFICER OF MINERVA WHILE RESIGNING HIS POSITION AS PRESIDENT.  Full Article

Minerva Neurosciences reports Q3 loss per share $0.28
Monday, 6 Nov 2017 07:30am EST 

Nov 6 (Reuters) - Minerva Neurosciences Inc :Minerva Neurosciences Inc reports third quarter 2017 financial results and business updates.Q3 loss per share $0.28.Q3 earnings per share view $-0.00 -- Thomson Reuters I/B/E/S.Minerva Neurosciences Inc - ‍expects cash, cash equivalents and marketable securities will be sufficient to fund operations for at least next 12 months​.Minerva Neurosciences Inc - ‍cash, cash equivalents, marketable securities as of Sept 30, were about $143.3 million, compared to $83.0 million as of Dec 31, 2016​.  Full Article

Minerva Neurosciences announces enrollment of first patient in phase 2b trial of seltorexant
Tuesday, 5 Sep 2017 08:00am EDT 

Sept 5 (Reuters) - Minerva Neurosciences Inc ::Minerva Neurosciences announces enrollment of first patient in phase 2b trial of seltorexant (min-202) as adjunctive therapy in patients with major depressive disorder.Minerva Neurosciences Inc - approximately 280 patients are planned to be enrolled at more than 85 clinical sites in U.S., Europe, Russia and Japan.  Full Article

Minerva Neurosciences announces enrollment of first patient in phase 2B trial of Seltorexant
Tuesday, 5 Sep 2017 08:00am EDT 

Sept 5 (Reuters) - Minerva Neurosciences Inc :Minerva Neurosciences announces enrollment of first patient in phase 2B trial of Seltorexant (MIN-202) as adjunctive therapy in patients with major depressive disorder.Approximately 280 patients are planned to be enrolled at more than 85 clinical sites in U.S., Europe, Russia and Japan​.  Full Article

Minerva Neurosciences announces European Commission approval of amendment of MIN-202 agreement with Janssen
Friday, 25 Aug 2017 08:30am EDT 

Aug 25 (Reuters) - Minerva Neurosciences Inc :Minerva Neurosciences announces European Commission approval of amendment of MIN-202 agreement with Janssen.Minerva Neurosciences Inc - ‍combined proceeds are expected to support anticipated data readouts from five planned clinical trials with three product candidates​.Minerva Neurosciences Inc - ‍payments to Minerva by Janssen under new agreement include an upfront payment of $30 million​.Minerva Neurosciences Inc - ‍Minerva has assumed all financial responsibility for phase 3 development costs for MIN-202 in insomnia​.Minerva Neurosciences Inc - ‍Janssen waived remaining payments due from Minerva for phase 2 development of MIN-202, which total approximately $13 million​.Minerva Neurosciences - ‍all Minerva stock previously owned by JJDC will be repurchased by Minerva at par value of $.0001/ share or about $389 in total​.Minerva Neurosciences Inc - ‍under amended agreement, Minerva gains control of development of MIN-202 to treat insomnia​.Minerva Neurosciences Inc - ‍under amended agreement Janssen foregoes its right to royalties on MIN-202 insomnia sales in Minerva territories​.Minerva Neurosciences Inc - ‍ Minerva retains its rights to MIN-202 as adjunctive therapy for major depressive disorder​.  Full Article

Minerva Neurosciences ‍says phase 2B trial with MIN-117 planned for late 2017​
Thursday, 3 Aug 2017 07:30am EDT 

Aug 3 (Reuters) - Minerva Neurosciences Inc :Minerva Neurosciences reports second quarter 2017 financial results and business updates.Q2 loss per share $0.27.Minerva Neurosciences Inc - ‍cash, cash equivalents and marketable securities as of June 30 were about $77.6 million, versus $83.0 million as of Dec 31, 2016​.Minerva Neurosciences Inc - ‍phase 2B clinical trial with MIN-117 in MDD is planned for initiation in late 2017​.  Full Article

Minerva Neurosciences Q2 loss per share $0.27
Thursday, 3 Aug 2017 07:30am EDT 

Aug 3 (Reuters) - Minerva Neurosciences Inc :Minerva Neurosciences reports second quarter 2017 financial results and business updates.Q2 loss per share $0.27.Minerva Neurosciences - ‍cash, cash equivalents & marketable securities as of June 30 were about $77.6 million, compared to $83.0 million as of Dec 31, 2016​.  Full Article

American Journal of Psychiatry publishes Minerva Neurosciences' MIN-101 Phase 2b trial results
Monday, 31 Jul 2017 08:30am EDT 

July 31 (Reuters) - Minerva Neurosciences Inc :American Journal of Psychiatry publishes Minerva Neurosciences' MIN-101 Phase 2b trial results for treatment of negative symptoms in Schizophrenia.Minerva Neurosciences - expects to initiate a pivotal phase 3 trial with MIN-101 to treat negative symptoms in Schizophrenia in H2 2017​.  Full Article

Minerva Neurosciences announces departure of directors
Monday, 24 Jul 2017 08:30am EDT 

July 24 (Reuters) - Minerva Neurosciences Inc ::Minerva Neurosciences announces departure of directors.Announced resignation of two members of its board of directors, Michele Ollier and Nico Vandervelpen.Minerva Neurosciences - Ollier and Vandervelpen will step down to focus on their private equity activities.  Full Article

Minerva Neurosciences prices 5 mln common shares at $7.75 per share
Wednesday, 28 Jun 2017 06:45pm EDT 

June 28 (Reuters) - Minerva Neurosciences Inc :Minerva neurosciences announces pricing of public offering of common stock.Says public offering of 5.00 million common shares priced at $7.75 per share.  Full Article

BRIEF-Minerva Neurosciences names Richard Russell president

* MINERVA NEUROSCIENCES INC - REMY LUTHRINGER WILL CONTINUE AS CHIEF EXECUTIVE OFFICER OF MINERVA WHILE RESIGNING HIS POSITION AS PRESIDENT Source text for Eikon: Further company coverage: